What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Upadacitinib demonstrated moderate clinical effectiveness compared to placebo, with statistically significant improvements in ACR 20 response and other secondary outcomes. However, it has not been directly compared with other biological DMARDs, leading to some uncertainty in its relative effectiveness.
Does the economic case hold at the expected price? — Cost effectiveness
Upadacitinib is considered cost-effective for patients who have had prior biological DMARDs or for whom TNFi treatments are contraindicated, with ICERs below £20,000 per QALY gained in these populations.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that psoriatic arthritis significantly impacts health-related quality of life. While upadacitinib is expected to improve HRQoL, the specific data on HRQoL improvements were not robustly detailed in the document.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of upadacitinib is generally favorable, with mostly mild to moderate adverse events reported. Serious adverse events are rare, indicating a good tolerability compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
While upadacitinib was compared with placebo and adalimumab, the lack of direct comparisons with other biological DMARDs limits the robustness of the evidence regarding its relative effectiveness.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial populations included relevant subgroups of patients with psoriatic arthritis, enhancing the generalizability of the findings. However, some limitations in subgroup analyses were noted.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Upadacitinib can be integrated into existing treatment pathways with minor adjustments, as it is an oral treatment option that does not require significant changes to current practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model indicates a high resource burden for patients who have not previously received a biological DMARD, raising concerns about its affordability in this population.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by pivotal trials, although the reliance on indirect comparisons introduces some uncertainty. Overall, the quality of evidence is acceptable.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the indirect comparisons and the economic model, particularly concerning the treatment sequences in clinical practice, which could impact decision-making.
